ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said Chairman and Chief Executive Tian Wenzhi acquired 50,000 H shares in the open market on Friday at an average price of HK$7.95 per share, according to a same-day Hong Kong bourse filing.
Shares of the firm were up nearly 2% in Monday's mid-day trade.
Following the purchase, Tian holds nearly 116.1 million shares, representing 26.9% of the company's issued share capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.